Skip to content
Search

Latest Stories

LloydsPharmacy’s Steve Howard announces retirement   

After 35 years of service, Professor Steve Howard has announced his retirement as LloydsPharmacy superintendent effective on December 31.

Howard, who also serves as the clinical standards director at McKesson UK, will continue as a part time non-executive adviser to the firm, overseeing its collective clinical standards and governance procedures and processes.


A succession plan is in place and will be announced in the next few weeks, the pharmacy chain has said.

Howard started his career as a clinical pharmacist in hospital before joining Lloyds as a pharmacy manager. Since then, he served in various roles including as head of internal communications and director of training and development.

Toby Anderson, chief executive at McKesson UK, said:  “Steve has made a great contribution throughout his career with our business and I would like to say a huge thank you to him for his dedication, service, leadership and professional guidance over the years and in particular during the recent considerable period of change.”

A graduate of Manchester University, Howard is a fellow of the Royal Pharmaceutical Society and a Faculty Fellow. He also serves as a visiting professor at the University of Huddersfield and the University of East Anglia.

More For You

After US and EU, UK approves Bavarian Nordic’s chikungunya vaccine

Bavarian Nordic plans to launch the vaccine in the UK in summer 2025

Getty Images

Chikungunya vaccine Vimkunya approved for use in the UK

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Vimkunya, a vaccine developed by Bavarian Nordic A/S to prevent chikungunya disease in people aged 12 years and older.

The UK approval follows earlier approvals by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025, making this the third regulatory green light for the vaccine.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less
Many patients report inaccuracies or missing details in their NHS medical records

Inaccurate information can result in serious harm or even death, warns Healthwatch England.

Image Credit: Getty Images

1 in 4 adults have spotted errors in their NHS medical records, survey finds

Healthwatch England has raised the alarm over the risks posed by inaccurate medical records as research reveals widespread errors in NHS patient information.

Commissioned by Healthwatch England and conducted by BMG Research, the survey polled a representative sample of 1,800 adults in England between 24 and 27 March 2025.

Keep ReadingShow less
Lib Dems condemn rising unsolved crimes, say shoplifting and burglary ‘effectively decriminalised’

Leicestershire police recorded the lowest charge rate for shoplifting in the country.

Gettyimages

Shoplifting and burglary ‘effectively decriminalised’, warn Lib Dems as unsolved crimes soar

The Liberal Democrats have raised alarm over what they describe as the “decriminalisation” of burglary and shoplifting, as new data reveals that the vast majority of such offences across Britain are going unsolved.

Figures revealed by the House of Commons Library research, commissioned by the party, showed that only 5.25 per cent of shoplifting offences in London last year led to a suspect being charged.

Keep ReadingShow less
RPS and HEIW extend independent prescribing learning programme for pharmacists in Wales

The programme is designed to support pharmacists delivering the Pharmacy Independent Prescribing Service in Wales.

gettyimages

Independent prescribing learning programme for pharmacists in Wales extended till 2028

The Royal Pharmaceutical Society (RPS) and Health Education and Improvement Wales (HEIW) have announced a three-year extension of their successful learning programme designed to support pharmacists delivering the Pharmacy Independent Prescribing Service (PIPS) in Wales.

Originally launched in 2024, the programme equips pharmacists with the essential knowledge, skills, and confidence needed to provide excellent patient care as independent prescribers.

Keep ReadingShow less